30.06.2022 - Pfizer Inc. (NYSE: PFE) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of PAXLOVID (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) for patients who are at high .
This Medical News feature examines the unexpected phenomenon of symptoms and positive test results recurring in Paxlovid users who’d a few days earlier felt fin
Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug Application Submission to U S FDA streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
NEW YORK Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Michigan, facility, enabling U.S.-based production in support of its CO